Previous 10 | Next 10 |
SILVER SPRING, Md., March 15, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release i...
SILVER SPRING, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that Dr. Randy Mills, P...
Aziyo Biologics ( NASDAQ: AZYO ) has announced preliminary net sales results for its fourth quarter and full year ended December 31, 2022. Aziyo Biologics is a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices an...
SILVER SPRING, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced preliminary (unau...
Follows recent equity financing, resulting in debt and equity gross proceeds of $15.2 million SILVER SPRING, Md., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving ...
SILVER SPRING, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced the pricing of it...
SILVER SPRING, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced that it has comme...
SILVER SPRING, Md., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced that management will be participati...
Aziyo Biologics, Inc. (AZYO) Q3 2022 Results Conference Call November 14, 2022 04:30 PM ET Company Participants Matt Steinberg - Fin Partners Randy Mills - CEO Matt Ferguson - CFO Conference Call Participants Josh Jennings - Cowen Simran Kaur - Pi...
Aziyo Biologics press release ( NASDAQ: AZYO ): Q3 GAAP EPS of -$0.73 misses by $0.07 . Revenue of $12.4M (+7.9% Y/Y) beats by $0.02M . Aziyo updated its expectation that total net sales for the full year 2022 will be in the range of $48 million to $50 million....
News, Short Squeeze, Breakout and More Instantly...
Aziyo Biologics Inc. Company Name:
AZYO Stock Symbol:
NASDAQ Market:
– Company to begin trading under new ticker symbol “ELUT” – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced a change of the Company’s name to Elutia Inc. The rebranding ref...
Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”...
Negotiating multiple LOIs to divest Orthopedic business CanGaroo ® RM 510(k) resubmission to the FDA remains on track SimpliDerm ® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular ...